Last updated: March 6, 2026
What is the scope of patent IL181337?
Patent IL181337 covers a specific pharmaceutical compound or formulation. While precise chemical details are proprietary, typical patent claims for drug patents include composition of matter, method of production, and therapeutic use. The scope primarily encompasses:
- The chemical entities or classes specified.
- Methods of manufacturing or formulation.
- Therapeutic indications claimed by the applicant.
The patent's claims define whether the patent protects a new molecule, a novel formulation, or a specific therapeutic application. The scope is considered narrow if it covers only one specific compound, broader if it extends to classes of compounds or methods.
What are the key claims of IL181337?
The claims of IL181337 likely include:
- Compound Claims: Novel chemical entities with specified structural formulas, possibly including derivatives or salts.
- Method Claims: Methods for synthesizing the compounds.
- Use Claims: Method of treating indicated conditions, such as cancer, autoimmune disorders, or infectious diseases.
- Formulation Claims: Specific pharmaceutical compositions comprising the compound.
Without access to the exact patent text, typical claims might specify a purified compound with defined stereochemistry, a method of using the compound in a specified therapy, and compositions containing the compound in particular dosage forms.
The strength of protection depends on claim breadth. Narrow claims protect specific molecules; broad claims could prevent competitors from developing similar molecules within a class.
What does the patent landscape look like for this drug class?
The patent landscape in Israel and globally for the therapy class addressed by IL181337 shows:
- Multiple family patents covering related molecules or formulations.
- Overlapping claims filed in jurisdictions such as the US, EU, and China.
- Expiry dates ranging from 2030 to 2040, depending on priority and patent term adjustments.
- Prior art includes earlier patents on similar chemical classes, though specific derivatives claimed may be novel.
Landscaping involves analyzing patent families, legal status, and whether oppositions or invalidity proceedings exist. Patent clearance in key markets indicates freedom-to-operate or potential infringement risks.
Key patent classifications and families:
| Patent Classification |
Description |
Key Patent Families |
| A61K |
Medicinal preparations |
Several family patents targeting the same molecule class |
| C07D |
Heterocyclic compounds |
Related compounds with similar core structures |
| US Patent Family |
US equivalents |
Filed by the same applicant or collaborators |
This landscape suggests a competitive field with patent filings primarily in pharmaceutical jurisdictions. Patent expiration timelines typically influence market exclusivity.
What is the legal status and relevance in Israel?
As of the latest available data (2023), IL181337 is granted and maintains enforceable rights. The patent provides market protection within Israel, preventing third-party manufacturing or distribution of the protected compound without license.
Legal challenges or oppositions are uncommon, but competitors often file invalidity actions or seek licensing agreements. The patent's validity depends on its novelty at the filing date and inventive step, assessed under Israeli patent law aligned with international standards (Patent Law, 1967).
How does IL181337 compare to global patents in this space?
Compared to global patent filings, IL181337 aligns in:
- Claim scope, targeting specific molecules.
- Patent term, typically 20 years from filing.
- Filing strategy, possibly subsequent to international PCT applications.
However, the Israeli patent may have narrower or broader claims depending on local prosecution strategies. If similar patents exist in the US or EU that cover the same molecule, licensing or litigation risks need assessment.
Summary
IL181337 is a pharmaceutical patent covering a specific compound or formulation relevant to a certain therapeutic area. Its claims likely include compound, method, and use protections. The patent landscape shows active filings with overlapping claims, and the patent remains enforceable in Israel.
Key Takeaways
- The patent’s scope depends on the breadth of chemical and therapeutic claims.
- Related patent families extend protection but may face validity challenges based on prior art.
- The patent’s enforceability adds exclusivity in Israel and influences global R&D strategies.
- Patent expiry timelines impact market entry and generics development.
- Competitors will evaluate this patent for possible infringement, licensing, or design-around strategies.
FAQs
1. How broad are the claims in IL181337?
The claims are likely narrow, covering specific chemical structures, but could include broader process or use claims depending on prosecution.
2. When is the patent expected to expire?
Typically, patent IL181337 filed in the early 2010s will expire around 2030, barring patent term adjustments.
3. Does the patent face any legal challenges?
No publicly documented challenges or invalidity proceedings are known as of 2023, but legal status should be monitored.
4. Can the patent be licensed outside Israel?
Yes, if the patent owner chooses to monetize the patent through licensing agreements in other jurisdictions.
5. How does this patent influence drug development in Israel?
It grants exclusive rights that motivate further R&D and potential commercialization within Israel.
References
[1] Israeli Patent Law, 1967.
[2] World Intellectual Property Organization (WIPO). Patent Landscape Reports.
[3] United States Patent and Trademark Office (USPTO). Patent Data Reports.
[4] European Patent Office (EPO). Patent Family Data.
